UBS Group’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.67M Sell
4,500
-14,000
-76% -$4.94M ﹤0.01% 5179
2026
Q2
$6.64M Buy
18,500
+4,500
+32% +$1.38M ﹤0.01% 3877
2026
Q1
$3.51M Hold
14,000
– – ﹤0.01% 4435
2025
Q4
$3.85M Hold
14,000
– – ﹤0.01% 4298
2025
Q3
$3.67M Buy
+14,000
New +$3.4M ﹤0.01% 4353
2015
Q1
– Sell
-500
Closed -$27K – 9452
2014
Q4
$27K Buy
+500
New +$25K ﹤0.01% 7234

Other funds holding WST

UBS Group's WST Position: Q3 2026 in Review

UBS Group reduced its West Pharmaceutical (WST) stake by 38% in Q3 2026, selling an estimated $50.4M and leaving 231,667 shares worth $85.9M. The position accounts for 0.01% of the portfolio, ranked #1215.

UBS Group first reported a position in WST in Q4 2014 and has held it in 48 quarters since. The position peaked at $134M in Q2 2026. 877 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • UBS Group held 231,667 shares of West Pharmaceutical worth $85.9M as of Q3 2026.
  • UBS Group sold 142,694 West Pharmaceutical shares in Q3 2026, an estimated $50.4M.
  • West Pharmaceutical made up 0.01% of UBS Group's portfolio in Q3 2026, its #1215 holding.
  • UBS Group first reported a position in West Pharmaceutical in Q4 2014 and has held it in 48 quarters since.
  • UBS Group's West Pharmaceutical position peaked at $134M in Q2 2026.
  • 877 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.